Clinical Trials Browser

Multiple Myeloma × Pharmaceutical Preparations × 90 days × Clear all

NCT05889221 2026-04-30

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

Phase NA Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell